ABSTRACT
Antiretroviral treatment (ART) use in India requires information on baseline drug resistance mutations and polymorphisms in the protease (Pr) and reverse transcriptase (RT) genes of HIV-1 strains from treatment-naïve individuals. We report resistance predictor mutations and polymorphisms in the Pr and the RT sequence of non-clade B HIV-1 strains from ART naïve individuals. The genotypic resistance assay was done on 93 treatment-naïve individuals. The sequences were analysed by Stanford HIV drug resistance data for genotypic drug resistance analysis and REGA HIV-1 subtyping tool. Phylogenetic tree was generated with MEGA 4 for quality control. Ninety-two strains belonged to clade C and one to clade A (A1). Amino acid substitutions were seen at positions associated with drug resistance in Pr gene--10, 24, 74 (each 3%) and position 82 (11%). Substitutions were seen at positions 41 (1%), 100 (1%), 101 (6%), 103 (2%), 179 (6%) and 181 (1%) of the RT sequence known to confer drug resistance in clade B. Polymorphisms in HIV-1 pol gene among treatment-naïve individuals were similar when compared with previous data. One strain each had Y181C substitution, T74S and E35G substitutions in the Pr and one had A98G, K101R and L210FL substitutions in RT.
Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Drug Resistance, Viral/genetics , HIV Protease/genetics , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , Mutation , Adolescent , Adult , Amino Acid Substitution , Base Sequence , Child , Female , Genotype , HIV-1/genetics , Humans , Male , Middle Aged , Molecular Sequence DataABSTRACT
BACKGROUND & OBJECTIVE: Bacterial resistance has greatly hampered effective treatment of patients in clinical settings. Non-fermenting Gram-negative bacilli (NFGNB) are common nosocomial pathogens. In this study we attempted to develop a convenient test for early detection of carbapenemase and metallo-beta-lactamase (MbetaL) production in NFGNB. Lack of sufficient reports from India in this area indicated the need for this study. METHODS: A total of 50 imipenem resistant NFGNB were speciated, and their resistance reconfirmed by disk diffusion and minimum inhibitory concentration (MIC) determination by agar dilution. Two different methods namely modified Hodge and EDTA disk synergy tests were evaluated for carbapenemase and metallo-beta-lactamase (MbetaL) production. RESULTS: Of the 50 imipenem resistant NFGNB, 48 and two respectively fell in the resistant and intermediate range in MIC using agar dilution. Majority of these were Pseudomonas aeruginosa (n=28), followed by Burkholderia cepacia (n=9). The modified Hodge test could detect 28 strains as carbapenemase and MbetaL producers, while the EDTA disk synergy test was able to detect an additional 8 strains producing MbetaL and carbapenemase. INTERPRETATION & CONCLUSION: Pseudomonas aeruginosa was found to be the predominant NFGNB in our hospital setting and EDTA disk synergy could detect more carbapenemase and metallo-beta- lactamase producers compared to modified Hodge test.
Subject(s)
Bacterial Proteins/blood , beta-Lactamases/blood , Anti-Bacterial Agents/pharmacology , Bacteria/classification , Bacteria/drug effects , Bacteria/isolation & purification , Drug Resistance, Microbial , Humans , Imipenem/pharmacology , Microbial Sensitivity TestsABSTRACT
The phylogenic analysis of the nucleotide sequences of the env gene has enabled classification of HIV-1 into three groups. The group M of HIV-1 infection has been classified into 9 different genetic subtypes A-K, with E and I being classified as circulating recombinants forms (CRFs). The groups O and N are less frequently encountered in human infections. Presently group M of HIV-1 globally causes 99.6 per cent of all human infections. The epidemiological trends suggest that subtype C strains would dominate the HIV pandemic in the coming years. The geographic spread of subtype C strains is also very diverse with prevalence in Africa, Latin America and Asia. Data from India show a high prevalence of subtype C. In north and western India, 78.4 and 96 per cent of HIV-1 strains respectively were shown to be subtype C. Among female sex workers in Kolkata 95 per cent of the HIV-1 strains were subtype C. The south Indian subtype data are very similar to the data from the rest of India. The HIV-2 groups (subtypes) recognized are A-H. Unlike HIV-1, HIV-2 strains are predominantly found in Africa. The Indian HIV-2 strains identified till date are subtype A. This is also the predominant strain circulating in western African countries. This group (subtype) is estimated to cause 0.11 per cent of all HIV infections in humans.
Subject(s)
HIV/genetics , Molecular Epidemiology , Genotype , HIV/classification , Humans , India , PhylogenyABSTRACT
PURPOSE: Autoimmune diseases usually manifest in genetically predisposed individuals following an environmental trigger. There are several viral infections including Epstein-Barr virus (EBV) implicated in the pathogenesis of autoimmune disorders. The aim of this study was to look at the antibody pattern to EBV proteins in the plasma of both systemic and organ specific autoimmune disorders, estimate pro-inflammatory plasma cytokines (IL-8 and TNF-alpha) among these autoimmune patients and compare the observations with those in normal healthy controls. MATERIALS AND METHODS: Samples from 44 rheumatoid arthritis patients, 25 Hashimoto's thyroiditis patients, appropriately age and sex matched healthy controls were tested for EBV IgM antibodies by an immunoblot assay and two cytokines (IL-8 and TNF-alpha) by commercial assays. RESULTS: Among the rheumatoid arthritis patients, 23 (52%) were positive for EBNA1 antibody, while 13 (52%) of the Hashimoto's thyroiditis patients and 12 (30%) of the healthy controls showed similar bands. The intensity of the bands was high in the autoimmune patients when compared to the bands seen in control samples. The difference in the EBNA1 reactivity between rheumatoid arthritis patients and controls were significant (P = 0.038). There was a significant difference in the IgM reactivity to VCAp19 protein between patients and controls (P = 0.011). CONCLUSION: Our study showed an increased EBV activation among the autoimmune patient groups compared to the normal healthy controls. Further studies are required to delineate the association between the aetiology of autoimmune disorders and EBV.
Subject(s)
Antibodies, Viral/blood , Arthritis, Rheumatoid/immunology , Autoimmune Diseases/immunology , Epstein-Barr Virus Infections/immunology , Hashimoto Disease/immunology , Herpesvirus 4, Human/immunology , Arthritis, Rheumatoid/etiology , Autoimmune Diseases/etiology , Case-Control Studies , Cytokines/blood , Epstein-Barr Virus Infections/complications , Female , Hashimoto Disease/etiology , Humans , Immunoglobulin M/blood , MaleABSTRACT
PURPOSE: There has been an increase in the number of individuals administered antiretroviral therapy (ART) in India but treatment outcome is hampered by increasing development of drug resistance. Previous reports from India have shown M184V as the commonest mutation in treated individuals. However, there is no evidence for any protease mutations in these reports. This study was done to observe the common/unique mutational patterns observed in reverse transcriptase (RT) and protease (Pr) genes of clade C HIV-1 strains from individuals showing treatment failure in India. MATERIALS AND METHODS: The assay was done by sequencing the Pr and RT genes of the HIV-1 strains from 18 individuals failing ART. Analysis was carried out using Stanford HIV drug resistance database (SHDB). The sequences were also submitted to the calibrated population resistance tool of SHDB and Rega HIV-1 sub typing tool. Phylogenetic analysis and quality control were performed with Mega 4. RESULTS: Among the 20 strains, 19 showed resistance to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), one strain to NNRTIs and five strains showed protease inhibitors (PI) resistance and 3-class resistance. The most common mutation conferring NRTI resistance was M184V (90%) while K103N (45%) was the most common mutation conferring NNRTI resistance. The M46I mutation was seen in 20% of the Pr sequences. CONCLUSION: Resistance testing to check the prevalence of drug resistance mutations that arise following failure of the first line regimen to establish guidelines for second line regimens in India is a must. Studies are needed to confirm if mutation patterns that arise among clade C following failure of ART are the same as for clade B strains.
Subject(s)
Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/methods , Drug Resistance, Viral , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/genetics , Mutation, Missense , Adolescent , Adult , Child , Female , HIV Protease/genetics , HIV Reverse Transcriptase/genetics , HIV-1/isolation & purification , Humans , India , Male , Middle Aged , Molecular Sequence Data , Sequence Analysis, DNA , Treatment Failure , Young AdultABSTRACT
HIV-1 subtypes other than B are responsible for most new HIV infections worldwide; virus sequence data for drug resistance is described only from a limited number of non-B subtype HIV-1. This study is on mutations and polymorphisms of HIV-1 protease gene that can predict drug resistance in subtype C. The genotypic resistance assay was carried out on 38 HIV-1 strains with their plasma RNA and in nine, the proviral protease gene was sequenced. The treatment naïve strains showed minor resistance mutations, there were no major resistance mutations in the protease gene. We suggest the use of resistance testing to monitor individuals on therapy and also before initiation of therapy, gathering more sequence information for a data bank of Indian strains.
Subject(s)
Drug Resistance, Viral/genetics , HIV Infections/virology , HIV Protease/genetics , HIV-1/drug effects , Amino Acid Substitution/genetics , Genotype , HIV-1/isolation & purification , Humans , India , Mutation, Missense , RNA, Viral/blood , RNA, Viral/genetics , RNA, Viral/isolation & purification , Sequence Analysis, DNAABSTRACT
The first HIV-1 marker that appears in blood following infection is HIV-1 RNA and usually the load is in millions of copies/ ml preceding seroconversion. A 24-year-old pregnant woman, gravida 2, parity 1 was tested for HIV as part of antenatal screening. Three samples were collected and tested from this individual over a period 70 days. The HIV-1 RNA level during seroconversion phase was very low, contrary to the well understood natural history of HIV infection. The reactivity rate in the ELISA and the Western Blot profile showed a gradual increase over the 70 days with a weak reactivity in a second generation assay (detects IgG only) for the third sample. This case illustrates the uncertainties regarding the serological window period in HIV infection and the need to use at least a third generation assay in testing centres for early detection of HIV infection.
Subject(s)
AIDS Serodiagnosis/standards , HIV Antibodies/blood , HIV Infections/diagnosis , HIV Seropositivity , HIV-1/immunology , Pregnancy Complications, Infectious/diagnosis , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , HIV Infections/immunology , HIV Infections/virology , Humans , Mass Screening/methods , Mass Screening/standards , Polymerase Chain Reaction , Pregnancy , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/virology , RNA, Viral/blood , Time Factors , Young AdultABSTRACT
PURPOSE: We have earlier documented that the south Indian population had lower CD4 counts. The aim of this study was to investigate a previous suggestion on a new CD4+ T cell cut off and association with HIV-1 RNA levels for decision on anti retroviral therapy in India (south). METHODS: We evaluated a new methodology i.e., artus real-time PCR and CD4+ T cell count by Guava EasyCD4 system. From 146 HIV infected individuals seen at a tertiary care centre, blood was collected for CD4+ T cell and HIV-1 RNA estimation. RESULTS: The receiver operating characteristic curve cut off value for the CD4 counts to distinguish between CDC clinical categories A and B was 243 cells/microL, and to distinguish B and C was 153 cells/microL. The RNA level that differentiated CDC A and B was 327473 RNA copies/mL, while for CDC B and C was 688543 copies/mL. There was a significant negative correlation (r = -0.55, P + T cell counts in HIV infected individuals. CONCLUSIONS: A majority with CD4 counts of 201-350 cells/microL in our population had higher viral load than the treatment threshold suggested by the International AIDS society and the above two methodologies are useful in monitoring HIV infections.
Subject(s)
HIV Infections/immunology , HIV Infections/virology , HIV-1/isolation & purification , Viral Load , CD4 Lymphocyte Count/methods , HIV Infections/drug therapy , Hospitals , Humans , India , Polymerase Chain Reaction/methods , RNA, Viral/blood , ROC Curve , Severity of Illness IndexABSTRACT
In developing countries, the usability of peripheral blood constituents that are low-cost alternatives to CD4-positive (CD4+) T-cell and human immunodeficiency virus type 1 (HIV-1) RNA estimation should be evaluated as prognostic markers. The aim of our study was to investigate the use of plasma levels of dehydroepiandrosterone sulfate (DHEAS), albumin, and C-reactive protein (CRP) as alternate prognostic markers for antiretroviral treatment (ART) response in place of HIV-1 load measurements. Paired blood samples were collected from 30 HIV-infected individuals before and after initiation of ART, 13 HIV-infected individuals before and after completion of antituberculosis therapy (ATT), and 10 HIV-infected individuals not on either ATT or ART. Because of the nonavailability of samples, the CRP estimation was done for samples from only 19, 9, and 8 individuals in groups 1, 2, and 3, respectively. The measurements of all three markers, i.e., DHEAS, albumin, and CRP, were carried out with commercial assays. The differences in the albumin levels before and after ART or ATT were significant (P < 0.05), while the differences in DHEAS and CRP levels were not significant (P > 0.05). When levels of DHEAS among the individuals who were followed up were analyzed, 13 (44.8%) in the ART group and 9 (69%) in the ATT group showed an increase following treatment. Prior to treatment of HIV-infected individuals, there was a significant positive correlation of CD4+ T-cell counts and a negative correlation of viral load with albumin and DHEAS levels (P < 0.01). Among the three plasma markers we tested, plasma albumin and, to some extent, DHEAS show promise as prognostic markers in monitoring HIV infection.
Subject(s)
C-Reactive Protein/metabolism , Dehydroepiandrosterone Sulfate/blood , HIV Infections/blood , HIV Infections/drug therapy , HIV-1/isolation & purification , Adult , Aged , Antiretroviral Therapy, Highly Active/methods , Antitubercular Agents/metabolism , Biomarkers/blood , CD4-Positive T-Lymphocytes/immunology , Developing Countries , Disease Progression , Female , HIV Infections/immunology , HIV Infections/virology , Humans , Male , Middle Aged , Prognosis , Serum Albumin/metabolism , Viral Load/methodsABSTRACT
The shift in cytokine profile during human immunodeficiency virus (HIV) disease progression is influenced by dehydroepiandrosterone sulfate (DHEAS) level. Radioimmunoassay was used to measure plasma DHEAS for 30 treatment-naïve HIV-infected and 30 uninfected individuals. There was a significant negative correlation of viral load with DHEAS level (P<0.05). Further studies of the use of DHEAS levels for monitoring HIV patients economically are warranted.
Subject(s)
Biomarkers/blood , Dehydroepiandrosterone Sulfate/blood , HIV Infections/blood , HIV Infections/virology , Adult , Female , Humans , India , Male , Middle Aged , Radioimmunoassay , Viral LoadABSTRACT
An alternative technology for the estimation of T cells based on a microcapillary technique (Guava Technologies, Hayward, CA) was compared to FACSCount (Becton Dickinson, San Jose, CA). Samples from 51 human immunodeficiency virus-infected and 21 healthy individuals were tested. The correlation (r) of the two systems for CD4(+) T cells was 0.994, and the coefficient of variation was 6.5%, establishing equable performance between the two technologies.